XML 22 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1Close
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Revenues    
Revenues $ 10,345 $ 10,710 Close
Costs and operating expenses:    
Selling, general and administrative expenses 2,183 2,119
Research and development expenses 331 346
Restructuring and other costs 29 112
Total costs and operating expenses 8,682 9,147 Close
Operating income 1,663 1,563 Close
Interest income 279 146 Close
Interest expense (363) (300) Close
Other income/(expense) 10 (46) CloseClose
Total Other Income Expenses -74.0 -200.0 0.0 0 0 Close
Income before income taxes 1,589 1,363 CloseClose
Provision for income taxes (281) (46) Close
Equity in earnings/(losses) of unconsolidated entities 23 (25) Close
Net income 1,331 1,292 Close
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest 4 3
Net income attributable to Thermo Fisher Scientific Inc. $ 1,328 $ 1,289
Earnings per share attributable to Thermo Fisher Scientific Inc.    
Basic (in dollars per share) $ 3.47 $ 3.34
Diluted (in dollars per share) $ 3.46 $ 3.32
Weighted average shares    
Basic (in shares) 382 386
Diluted (in shares) 384 388
Product revenues    
Revenues    
Revenues $ 5,955 $ 6,404
Costs and operating expenses:    
Cost of revenues 2,939 3,337
Service revenues    
Revenues    
Revenues 4,390 4,306
Costs and operating expenses:    
Cost of revenues $ 3,201 $ 3,233